|
1
|
Kalamarides M, Stemmer-Rachamimov AO,
Niwa-Kawakita M, Chareyre F, Taranchon E, Han ZY, Martinelli C,
Lusis EA, Hegedus B, Gutmann DH and Giovannini M: Identification of
a progenitor cell of origin capable of generating diverse
meningioma histological subtypes. Oncogene. 30:2333–2344.
2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tohma Y, Yamashima T and Yamashita J:
Immunohistochemical localization of cell adhesion molecule
epithelial cadherin in human arachnoid villi and meningiomas.
Cancer Res. 52:1981–1987. 1992.PubMed/NCBI
|
|
3
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2011-2015. Neuro Oncol. 20 (suppl_4):iv1–iv86.
2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gunadi SV, Suryanti S and Yohana R: The
distribution of meningioma in Dr. Hasan Sadikin general hospital
bandung period 2010-2013. Althea Med J. 5:157–160. 2018.
|
|
5
|
Wiemels J, Wrensch M and Claus EB:
Epidemiology and etiology of meningioma. J Neurooncol. 99:307–314.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Preusser M, Brastianos PK and Mawrin C:
Advances in meningioma genetics: Novel therapeutic opportunities.
Nat Rev Neurol. 14:106–115. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Du Z, Abedalthagafi M, Aizer AA, McHenry
AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK,
Reardon DA, et al: Increased expression of the immune modulatory
molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget.
6:4704–4716. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bi WL, Zhang M, Wu WW, Mei Y and Dunn IF:
Meningioma genomics: Diagnostic, prognostic, and therapeutic
applications. Front Surg. 3(40)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suppiah S, Nassiri F, Bi WL, Dunn IF,
Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C,
Noushmehr H, et al: Molecular and translational advances in
meningiomas. Neuro Oncol. 21 (Suppl 1):i4–i17. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang JZ, Patil V, Landry AP, Gui C,
Ajisebutu A, Liu J, Saarela O, Pugh SL, Won M, Patel Z, et al:
Molecular classification to refine surgical and radiotherapeutic
decision-making in meningioma. Nat Med. 30:3173–3183.
2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nazem AA, Ruzevick J and Ferreira MJ Jr:
Advances in meningioma genomics, proteomics, and epigenetics:
Insights into biomarker identification and targeted therapies.
Oncotarget. 11:4544–4553. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Abedalthagafi M, Bi WL, Aizer AA, Merrill
PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D,
Thorner AR, Van Hummelen P, et al: Oncogenic PI3K mutations are as
common as AKT1 and SMO mutations in meningioma. Neuro Onco.
18:649–655. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Clark VE, Erson-Omay EZ, Serin A, Yin J,
Cotney J, Ozduman K, Avşar T, Li J, Murray PB, Henegariu O, et al:
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7,
KLF4, AKT1, and SMO. Science. 339:1077–1080. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Proctor DT, Ramachandran S, Lama S and
Sutherland GR: Towards molecular classification of meningioma:
Evolving treatment and diagnostic paradigms. World Neurosurg.
119:366–373. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Halabi R, Dakroub F, Haider MZ, Patel S,
Amhaz NA, Reslan MA, Eid AH, Mechref Y, Darwiche N, Kobeissy F, et
al: Unveiling a biomarker signature of meningioma: The need for a
panel of genomic, epigenetic, proteomic, and RNA biomarkers to
advance diagnosis and prognosis. Cancers (Basel).
15(5339)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kerr K, Qualmann K, Esquenazi Y, Hagan J
and Kim DH: Familial syndromes involving meningiomas provide
mechanistic insight into sporadic disease. Neurosurgery.
83:1107–1118. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zankl H and Zang KD: Cytological and
cytogenetical studies on brain tumors. 4. Identification of the
missing G chromosome in human meningiomas as no. 22 by fluorescence
technique. Humangenetik. 14:167–169. 1972.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Weber RG, Boström J, Wolter M, Baudis M,
Collins VP, Reifenberger G and Lichter P: Analysis of genomic
alterations in benign, atypical, and anaplastic meningiomas: Toward
a genetic model of meningioma progression. Proc Natl Acad Sci USA.
94:14719–14724. 1997.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Smith MJ: Germline and somatic mutations
in meningiomas. Cancer Genet. 208:107–114. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Goutagny S, Yang HW, Zucman-Rossi J, Chan
J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS and
Kalamarides M: Genomic profiling reveals alternative genetic
pathways of meningioma malignant progression dependent on the
underlying NF2 status. Clin Cancer Res. 16:4155–4164.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Youngblood MW, Miyagishima DF, Jin L,
Gupte T, Li C, Duran D, Montejo JD, Zhao A, Sheth A, Tyrtova E, et
al: Associations of meningioma molecular subgroup and tumor
recurrence. Neuro Oncol. 23:783–794. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Loewenstern J, Rutland J, Gill C, Arib H,
Pain M, Umphlett M, Kinoshita Y, McBride R, Donovan M, Sebra R, et
al: Comparative genomic analysis of driver mutations in matched
primary and recurrent meningiomas. Oncotarget. 10:3506–3517.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Berghoff AS, Hielscher T, Ricken G,
Furtner J, Schrimpf D, Widhalm G, Rajky U, Marosi C, Hainfellner
JA, von Deimling A, et al: Prognostic impact of genetic alterations
and methylation classes in meningioma. Brain Pathol.
32(e12970)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bouwmeester T, Bauch A, Ruffner H, Angrand
PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J,
Ghidelli S, et al: A physical and functional map of the human
TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol.
6:97–105. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yuzawa S, Nishihara H and Tanaka S:
Genetic landscape of meningioma. Brain Tumor Pathol. 33:237–247.
2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tetreault MP, Yang Y and Katz JP:
Krüppel-like factors in cancer. Nat Rev Cancer. 13:701–713.
2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Brembeck FH and Rustgi AK: The
tissue-dependent keratin 19 gene transcription is regulated by
GKLF/KLF4 and Sp1. J Biol Chem. 275:28230–28239. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Janku F, Yap TA and Meric-Bernstam F:
Targeting the PI3K pathway in cancer: Are we making headway? Nat
Rev Clin Oncol. 15:273–291. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Brastianos PK, Horowitz PM, Santagata S,
Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen
P, Ducar MD, et al: Genomic sequencing of meningiomas identifies
oncogenic SMO and AKT1 mutations. Nat Genet. 45:285–289.
2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Keppler-Noreuil KM, Baker EH, Sapp JC,
Lindhurst MJ and Biesecker LG: Somatic AKT1 mutations cause
meningiomas colocalizing with a characteristic pattern of cranial
hyperostosis. Am J Med Genet A. 170:2605–2610. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Aavikko M, Li SP, Saarinen S, Alhopuro P,
Kaasinen E, Morgunova E, Li Y, Vesanen K, Smith MJ, Evans DG, et
al: Loss of SUFU function in familial multiple meningioma. Am J Hum
Genet. 91:520–526. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wicking C, Smyth I and Bale A: The
hedgehog signalling pathway in tumorigenesis and development.
Oncogene. 18:7844–7851. 1999.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Boetto J, Bielle F, Sanson M, Peyre M and
Kalamarides M: SMO mutation status defines a distinct and frequent
molecular subgroup in olfactory groove meningiomas. Neuro Oncol.
19:345–351. 2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zadeh G, Karimi S and Aldape KD: PIK3CA
mutations in meningioma. Neuro Oncol. 18:603–604. 2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Saura C, Bendell J, Jerusalem G, Su S, Ru
Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, et al:
Phase Ib study of buparlisib plus trastuzumab in patients with
HER2-positive advanced or metastatic breast cancer that has
progressed on Trastuzumab-based therapy. Clin Cancer Res.
20:1935–1945. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Koelsche C, Sahm F, Capper D, Reuss D,
Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, et
al: Distribution of TERT promoter mutations in pediatric and adult
tumors of the nervous system. Acta Neuropathol. 126:907–915.
2013.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gao K, Li G, Qu Y, Wang M, Cui B, Ji M,
Shi B and Hou P: TERT promoter mutations and long telomere length
predict poor survival and radiotherapy resistance in gliomas.
Oncotarget. 7:8712–8725. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mirian C, Duun-Henriksen AK, Juratli T,
Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny
S, Bertero L, et al: Poor prognosis associated with TERT gene
alterations in meningioma is independent of the WHO classification:
An individual patient data meta-analysis. J Neurol Neurosurg
Psychiatry. 91:378–387. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sahm F, Schrimpf D, Olar A, Koelsche C,
Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, et
al: TERT promoter mutations and risk of recurrence in meningioma. J
Natl Cancer Inst. 108(djv377)2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hadfield KD, Smith MJ, Trump D, Newman WG
and Evans DG: SMARCB1 mutations are not a common cause of multiple
meningiomas. J Med Genet. 47:567–568. 2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Van den Munckhof P, Christiaans I, Kenter
SB, Baas F and Hulsebos TJ: Germline SMARCB1 mutation predisposes
to multiple meningiomas and schwannomas with preferential location
of cranial meningiomas at the falx cerebri. Neurogenetics. 13:1–7.
2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Smith MJ, Wallace AJ, Bennett C,
Hasselblatt M, Elert-Dobkowska E, Evans LT, Hickey WF, van Hoff J,
Bauer D, Lee A, et al: Germline SMARCE1 mutations predispose to
both spinal and cranial clear cell meningiomas. J Pathol.
234:436–440. 2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Guyot A, Duchesne M, Robert S, Lia AS,
Derouault P, Scaon E, Lemnos L, Salle H, Durand K and Labrousse F:
Analysis of CDKN2A gene alterations in recurrent and non-recurrent
meningioma. J Neurooncol. 145:449–459. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Boström J, Meyer-Puttlitz B, Wolter M,
Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP and
Reifenberger G: Alterations of the tumor suppressor genes CDKN2A
(p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C
(p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol.
159:661–669. 2001.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Sievers P, Hielscher T, Schrimpf D,
Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin
C, Ketter R, et al: CDKN2A/B homozygous deletion is associated with
early recurrence in meningiomas. Acta Neuropathol. 140:409–413.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Peyre M, Stemmer-Rachamimov A,
Clermont-Taranchon E, Quentin S, El-Taraya N, Walczak C, Volk A,
Niwa-Kawakita M, Karboul N, Giovannini M and Kalamarides M:
Meningioma progression in mice triggered by Nf2 and Cdkn2ab
inactivation. Oncogene. 32:4264–4272. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Prasad RN, Gardner UG, Yaney A, Prevedello
DM, Koboldt DC, Thomas DL, Mardis ER and Palmer JD: Germline BAP1
mutation in a family with multi-generational meningioma with
rhabdoid features: A case series and literature review. Front
Oncol. 11(721712)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
LaFave LM, Béguelin W, Koche R, Teater M,
Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T,
Konstantinoff K, et al: Loss of BAP1 function leads to
EZH2-dependent transformation. Nat Med. 21:1344–1349.
2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Shankar GM and Santagata S: BAP1 mutations
in high-grade meningioma: Implications for patient care. Neuro
Oncol. 19:1447–1456. 2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Murnyák B, Bognár L, Klekner Á and
Hortobágyi T: Epigenetics of meningiomas. Biomed Res Int.
2015(532451)2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Birzu C, Peyre M and Sahm F: Molecular
alterations in meningioma: Prognostic and therapeutic perspectives.
Curr Opin Oncol. 32:613–622. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Pawloski JA, Fadel HA, Huang YW and Lee
IY: Genomic biomarkers of meningioma: A focused review. Int J Mol
Sci. 22(10222)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Sahm F, Schrimpf D, Stichel D, Jones DTW,
Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE,
Capper D, et al: DNA methylation-based classification and grading
system for meningioma: A multicentre, retrospective analysis.
Lancet Oncol. 18:682–694. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Gendreau JL, Chow KKH, Sussman ES, Iyer A,
Pendharkar AV and Ho AL: DNA methylation analysis for the treatment
of meningiomas. J Vis Surg. 3(178)2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Delgado-López PD, Cubo-Delgado E,
González-Bernal JJ and Martín-Alonso J: A practical overview on the
molecular biology of meningioma. Curr Neurol Neurosci Rep.
20(62)2020.PubMed/NCBI View Article : Google Scholar
|
